# Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients

**Supplementary Materials**



**Supplementary Figure 1: The optimal cutoff point for the SIRI was determined by ROC analysis in the training cohort.** The Youden index (sensitivity+specificity-1) was used to select a threshold for estimating sensitivity and specificity.

**Supplementary Table 1: Baseline characteristics in different SIRI group of validation cohort**

| Variable | SIRI < 1.05 | SIRI ≥ 1.05 | *P* value |
|---|---|---|---|
| No. of patients | 105 | 78 | |
| Age, years, Mean ± SD | 53.8 ± 11.6 | 53.7 ± 9.0 | 0.970 |
| Gender | | | 0.103 |
|   Male | 85 | 70 | |
|   Female | 20 | 8 | |
| Hepatitis B, *n* (%) | 92 (88) | 64 (82) | 0.295 |
| Cirrhosis (no vs yes) | 11 vs 94 | 9 vs 69 | 0.820 |
| Child-Pugh | | | 0.481 |
|   A | 95 | 68 | |
|   B | 10 | 10 | |
| AFP | | | 0.015 |
|   < 200 ng/ml | 53 | 26 | |
|   ≥ 200 ng/ml | 52 | 52 | |
| BCLC | | | 0.022 |
|   B | 65 | 35 | |
|   C | 40 | 43 | |
| TBIL (umol/L), mean ± SD | 18.3 ± 14.0 | 18.0 ± 9.2 | 0.847 |
| DBIL (umol/L), mean ± SD | 6.9 ± 8.5 | 7.1 ± 5.1 | 0.843 |
| ALT (IU/L), mean ± SD | 41.4 ± 38.5 | 53.9 ± 60.6 | 0.092 |
| AST (IU/L), mean ± SD | 48.5 ± 46.9 | 78.0 ± 79.0 | 0.004 |
| GGT (IU/L), mean ± SD | 124.6 ± 124.5 | 232.6 ± 243.2 | 0.001 |
| LDH (IU/L), mean ± SD | 202.1 ± 90.4 | 286.1 ± 185.2 | 0.000 |
| ALP (IU/L), mean ± SD | 121.9 ± 79.9 | 174.4 ± 136.5 | 0.003 |
| ALB (IU/L), mean ± SD | 40.1 ± 4.4 | 37.8 ± 4.8 | 0.002 |